Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNFα) production and TNFα-mRNA accumulation in human blood monocytes

Immunopharmacology

Volumn 35, Issue 3, 1997, Pages 265-271

  Siedlar, Maciej ^a   Szczepanik, Antoni ^b   Wiȩckiewicz, Jerzy ^a   Pituch Noworolska, Anna ^a   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

lipopolysaccharide; monocytes; tumor necrosis factor alpha; vancomycin

Indexed keywords

CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MACROPHAGE; MONOCYTE; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SEPTIC SHOCK; SUPERNATANT;

ANIMALS; ANTI-BACTERIAL AGENTS; DOWN-REGULATION; DRUG INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; RNA, MESSENGER; STIMULATION, CHEMICAL; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VANCOMYCIN;

EID: 0031041749     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(96)00156-7     Document Type: Article

References (20)

1. Agarwal S, Piesco NP, Johns LP, Riccelli AE. Differential expression of IL-1β, TNF-α, IL-6, and IL-8 in human monocytes in response to lipopolysaccharides from different microbes. J Dent Res 1995; 74: 1057-1065.
2. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev Biochem 1988; 57: 505-518.
3. Cooper GL, Given DB. Vancomycin. A comprehensive review of 30 years of clinical experience. Eli Lilly, 1986; 39-69.
4. Crosby HA, Bion JF, Penn CW, Elliott TS. Antibiotic-induced release of endotoxin from bacteria in vitro. J Med Microbiol 1994; 40: 23-30.
5. Debets JMH, Kampmeijer R, Van der Linden MPH, Burman WA, Van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489-93.
6. Dziarski R. Effects of peptidoglycan on the cellular components of the immune system. In: HP Seidl, KH Schleifer Eds. Biological Properties of Peptidoglycan. Berlin: De Gruyter, 1986; 229-242.
7. Foca A, Matera G, Berlinghieri MC. Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood. Eur J Clin Microbiol Infect Dis 1993; 12: 940-944.
8. Gupta D, Jin Y-p, Dziarski R. Peptidoglycan induces transcription and secretion of TNFα and activation of lyn, extracellular signal-regulated kinase, and rsk signal transduction proteins in mouse macrophages. J Immunol 1995; 155: 2620-2630.
9. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-21.
10. Heymer B, Seidl PH, Schleifer KH. Immunochemistry and biological activity of peptidoglycan. In: DES Stewart-Tull, M Davies Eds. Immunology of the Bacterial Cell Envelope. New York: Wiley, 1985; 11-28.
11. Hurley JC. Antibiotic-induced release of endotoxin: a reappraisal. Clin Infect Dis 1992; 15: 840-854.
12. Mattsson E, Verhage L, Rollof J, Fleer A, Verhoef J, Van Dijk H. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6. FEMS Immunol. Med Microbiol 1993; 7: 281-287.
13. Mohler J, Fantin B, Mainardi JL, Carbon C. Influence of antimicrobial therapy on kinetics of tumor necrosis factor levels in experimental endocarditis caused by Klebsiella pneumoniae. Antimicr Agents Chemother 1994; 38: 1017-1022.
14. Pugin J, Heumann D, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-520.
15. Suter PM, Suter S, Giradin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitor, interleukin-1, interferon and elastase in patients with adult respiratory distress syndrome after trauma, shock or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022.
16. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
17. Weidemann B, Brade H, Rietschel ET, Dziarski R, Bazil V, Kusumoto S, Flad H-D, Ulmer AJ. Soluble peptydoglycan-induced monokine production can be blocked by anti-CD14 monoclonal antibodies and by lipid A partial structures. Infect Immunol 1994; 62: 4709-4720.
18. Zabel P, Schade FU. Pentoxifylline and tumour necrosis factor-induced lung injury. Eur Respir J 1994; 7: 1389-1391.
19. Zembala M, Czupryna A, Wiȩckiewicz J, Jasiński M, Pryjma J, Ruggiero I, Siedlar M, Popiela T. Tumour-cell-induced production of tumour necrosis factor by monocytes of gastric cancer patients receiving BCG immunotherapy. Cancer Immunol Immunother 1993; 36: 127-132.
20. Zembala M, Siedlar M, Ruggiero I, Wiȩckiewicz J, Mytar B, Mattei M, Colizzi V. The MHC class-II and CD44 molecules are involved in the induction of tumour necrosis factor (TNF) gene expression by human monocytes stimulated with tumour cells. Int J Cancer 1994; 56: 269-274.